215P Real-world survival outcomes by risk features in patients with HR+, HER2− early breast cancer (EBC) in the US

This is the authors' abstract. We don't add key points for this paper.

Patients (pts) with node-positive (N+) high-risk clinicopathologic features in the monarchE trial (N+ High-Risk: N1 with Grade 3 [G3] or tumor ≥5 cm; N2; N3) have a real-world (RW) 5-year (y) recurrence risk of 30% on endocrine therapy (ET). In monarchE, 2-y of abemaciclib + ET improved invasive disease-free survival (IDFS) (hazard ratio [HR]=0.68, 5-y rates: 84% abemaciclib + ET vs 76% ET, 8% 5-y absolute benefit). This RW study described overall survival (OS) and IDFS in pts with monarchE high-risk features and in pts with triple negative EBC (TNBC) for context.